Crystalline epinephrine malonate salt
Described herein are epinephrine salts, specifically the epinephrine malonate salt; the epinephrine malonate salt in crystalline form; a pharmaceutical composition comprising epinephrine malonate; a sublingual or buccal pharmaceutical composition comprising epinephrine malonate in crystalline form; and a method for treating a patient comprising administering a pharmaceutical composition of epinephrine malonate in crystalline form.
1. An epinephrine malonate salt in crystalline form.
2. The epinephrine malonate salt of claim 1 , wherein the crystalline form has an x-ray powder diffraction spectrum (copper, K-alpha-1) having one or more peaks expressed as 2 theta at about 12.1843, 13.4653, 14.2595, 14.6991, 15.8664, 17.3570, 17.9004, 19.5883, 20.4659, 21.5801, 22.3908, 22.9301, 23.8776, 24.6585, 25.3418, 26.0105, 26.4829, 25.3418, 26.0105, 26.4829, 27.2385, 27.8939, 29.4741, 33.2425, 34.2629, 34.8439.
3. A pharmaceutical composition comprising epinephrine malonate salt and a pharmaceutically acceptable carrier.
4. The pharmaceutical composition of claim 3 , wherein the pharmaceutical composition is suitable for oral, rectal, intragastrical, topical, intracranial, intranasal, and parenteral administration.
5. The pharmaceutical composition of claim 3 , wherein the pharmaceutical composition is suitable for sublingual or buccal administration.
6. The pharmaceutical composition of claim 5 , wherein the pharmaceutical composition comprises a filler and a disintegrant.
7. The pharmaceutical composition of claim 6 , wherein the filler is microcrystalline cellulose and the disintegrant is cross-linked polyvinyl polypyrrolidone.
8. The pharmaceutical composition of claim 7 , wherein the filler is present in an amount of 20 to 30% by weight and the disintegrant is present in an amount of 5 to 15% by weight.
9. The pharmaceutical composition of claim 8 , further comprising a lubricant and a glidant.
10. The pharmaceutical composition of claim 9 , wherein the lubricant is magnesium stearate and the glidant is silicon dioxide.
11. The pharmaceutical composition of claim 10 , further comprising a diluent.
12. The pharmaceutical composition of claim 11 , wherein the diluent is mannitol.
13. The pharmaceutical composition of claim 12 , further comprising citric acid.
14. The pharmaceutical composition of claim 5 , wherein the composition comprises an amount of 0.3 to 10 mg of epinephrine free base.
15. The pharmaceutical composition of claim 5 , wherein the pharmaceutical composition disintegrates in less than or equal to 30 seconds.